DOI: 10.1128/AAC.02327-20
Article Information
PubMed
Published By
History
- Received November 5, 2020
- Accepted December 6, 2020
- Published online February 17, 2021.
Copyright & Usage
Copyright © 2021 Keating et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Article Versions
- Accepted Manuscript version (December 14, 2020).
- You are viewing the most recent version of this article.
Author Information
- Claire L. Keatinga,
- Jonathan B. Zuckermanb,
- Pradeep K. Singhc,
- Matthew McKevittd,
- Oksana Gurtovayae,
- Mark Bresnike,
- Bruce C. Marshallf and
- Lisa Saimang
- on behalf of the CFFPR-AZLI Study Group
- aDivision of Pulmonary, Allergy and Critical Care, Columbia University Irving Medical Center, New York, New York, USA
- bDivision of Pulmonary and Critical Care, Maine Medical Center, Portland, Maine, USA
- cDepartment of Microbiology and Medicine, University of Washington, Seattle, Washington, USA
- dGilead Sciences, Inc., Seattle, Washington, USA
- eGilead Sciences, Inc., Foster City, California, USA
- fCystic Fibrosis Foundation, Bethesda, Maryland, USA
- gDepartment of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA
- Address correspondence to Claire L. Keating, ck2132{at}cumc.columbia.edu.
Citation Keating CL, Zuckerman JB, Singh PK, McKevitt M, Gurtovaya O, Bresnik M, Marshall BC, Saiman L, on behalf of the CFFPR-AZLI Study Group. 2021. Pseudomonas aeruginosa susceptibility patterns and associated clinical outcomes in people with cystic fibrosis following approval of aztreonam lysine for inhalation. Antimicrob Agents Chemother 65:e02327-20. https://doi.org/10.1128/AAC.02327-20.
